Literature DB >> 26544574

Hit me with your best shot: dolutegravir - a space in the next WHO guidelines?

Jennifer Cohn1, Linda-Gail Bekker, Helen Bygrave, Alexandra Calmy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26544574     DOI： 10.1097/QAD.0000000000000813

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Reduced Effectiveness of Contraceptive Implants for Women Taking the Antiretroviral Efavirenz (EFV): Still Good Enough and for How Long?

Authors:  James D Shelton
Journal:  Glob Health Sci Pract       Date:  2015-12-08

Review 2.  Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.

Authors:  Bluma G Brenner; Ruxandra-Ilinca Ibanescu; Isabelle Hardy; Michel Roger
Journal:  Viruses       Date:  2017-12-28       Impact factor: 5.048

3.  Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.

Authors:  Pedro Cahn; María José Rolón; María Inés Figueroa; Ana Gun; Patricia Patterson; Omar Sued
Journal:  J Int AIDS Soc       Date:  2017-05-09       Impact factor: 5.396

4.  Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy.

Authors:  Mark A Wainberg; Thibault Mesplede
Journal:  J Int AIDS Soc       Date:  2015-12-04       Impact factor: 5.396

5.  The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.

Authors:  Amy Zheng; Nagalingeswaran Kumarasamy; Mingshu Huang; A David Paltiel; Kenneth H Mayer; Bharat B Rewari; Rochelle P Walensky; Kenneth A Freedberg
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

6.  Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Authors:  José M Gatell; Lambert Assoumou; Graeme Moyle; Laura Waters; Margaret Johnson; Pere Domingo; Julie Fox; Esteban Martinez; Hans-Jürgen Stellbrink; Giovanni Guaraldi; Mar Masia; Mark Gompels; Stephane De Wit; Eric Florence; Stefan Esser; François Raffi; Anton L Pozniak
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.